Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms.
Bristol-Myers Squibb (BMS) and Catalent have announced that Catalent has agreed to purchase BMS’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. The companies anticipate completing the transaction by the end of 2019.
Through the years, the Anagni plant has served as one of the primary launch facilities for new medicines from BMS that have helped millions of people in the fight against serious diseases such as cancer and cardiovascular disease. Upon closing, Catalent will continue to manufacture BMS’s current product portfolio at the site.
By enhancing its own global network with the Anagni plant, Catalent will bring potential new customers to the site for both biologics and oral solid dose manufacturing and packaging. In particular, this facility will provide Catalent biologics customers with access to an advanced sterile drug product fill/finish and packaging capacity in Europe to complement its existing sterile fill/finish capabilities in Belgium and its drug substance, analytical and fill/finish capabilities in North America.
We believe that the sale to Catalent will continue the vital role the Anagni facility plays for its workforce, the community and patients. This marks an important step in the ongoing evolution of our manufacturing network to support the company’s innovative product portfolio. BMS has a long history in Italy, and we intend to maintain a continued strategic presence in Italy, which is critical for our ability to deliver transformational medicines to patients,
said Lou Schmukler, President,
Global Product Development and Supply, BMS.
The addition of the Anagni facility provides our European customers with great biologics and oral dose capabilities to accelerate their development programs and improve commercial supply.” He added: “BMS has invested in the facility to create a center of excellence for new product launches with a robust quality and delivery record, and an employee base who shares Catalent’s operational excellence and patient focus,
Catalent’s President and Chief Operating Officer, commented.